[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-345420-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-345420-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","clinical-presentations-and-prognostication-of-her2-low-and-her2-zero-early-breast-cancer-in-taiwan","Clinical presentations and prognostication of HER2-low and HER2-zero early breast cancer in Taiwan","","Human epidermal growth factor receptor II (HER2)-low breast cancer has emerged as a clinically relevant subset within HER2-negative disease, but its prognostic meaning in real-world early-stage populations remains unclear. This study compared clinicopathological features and outcomes of HER2-low versus HER2-zero early breast cancers using Taiwan Cancer Registry data from 2011–2020, focusing on how hormone receptor (HR) status influences survival.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/clinical-presentations-and-prognostication-of-her2-low-and-her2-zero-early-breast-cancer-in-taiwan/345420/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/clinical-presentations-and-prognostication-of-her2-low-and-her2-zero-early-breast-cancer-in-taiwan/345420.png","ImageObject",300,407,{"name":42,"@type":43},"Asher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main goal of the study on HER2-low versus HER2-zero early breast cancer?","Question",{"text":63,"@type":64},"To compare clinicopathological features and outcomes of HER2-low versus HER2-zero early breast cancers and clarify the role of hormone receptor (HR) status in prognosis.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were eligible patients selected for analysis?",{"text":68,"@type":64},"Eligible cases were stages 0 to III HER2-negative breast cancers treated with upfront surgery, identified from the Taiwan Cancer Registry between 2011 and 2020.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key survival findings for HER2-low compared with HER2-zero after HR and stage stratification?",{"text":72,"@type":64},"Across HR- and stage-defined strata, HER2-low showed modestly higher hazards and small but consistent reductions in overall survival (OS) and relapse-free survival (RFS) versus HER2-zero, except for stage 0 where differences were not evident.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},345420,1790511082,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":124,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","J Chin MedAssoc  \nOriginal article  \nClinical presentations and prognostication of HER2-low and HER2-zero early breast cancer in Taiwan  \nYen-Jen Grace Chena,b,c, Pei-Ju Liena,b, Ling-Ming Tsenga,b,c,*, Chi-Cheng Huanga,b,d,*  \naDivision of Breast Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan; bComprehensive Breast Health Center, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan; cSchool of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; dInstitute of Epidemiology and Preventive Medicine, National Taiwan University, Taipei, Taiwan  \nAbstract  \nBackground: Human epidermal growth factor receptor II (HER2)-low breast cancer has emerged as a clinically relevant subset of HER2-negative disease, but its prognostic significance in early-stage, real-world populations remains uncertain. We aimed to compare clinicopathological features and outcomes of HER2-low vs HER2-zero early breast cancers using a nationwide registry and to clarify the impact of hormone receptor (HR) status.  \nMethods: We conducted a retrospective cohort study using the Taiwan Cancer Registry (2011-2020) . Eligible cases were stages 0 to III HER2-negative breast cancers managed with upfront surgery. We compared clinical characteristics , overall survival (OS) and relapse-free survival (RFS) . All analyses were stratified by HR (positive vs negative) and by pathological stage.  \nResults: We analyzed 38 773 patients; 65.4% were HER2-low and 34.6% were HER2-zero. HER2-low tumors were diagnosed at a slightly younger age (median 56.3 vs 57.1 years; p \u003C 0 .001) and were more often HR-positive. Across HR-and stage-defined strata, pathological stage and HR status remained the principal determinants of prognosis. Compared with HER2-zero, HER2-low showed modestly higher hazards, with small but consistent separations in OS (91 .8%, 93%, 83.3%, and 86.2% for HR-positive/ HER2-low, HR-positive/HER2-zero, HR-negative/HER2-low, and HR-negative/HER2-zero breast cancers; p \u003C 0.0001) and RFS (95 .6%, 97. 1%, 89.6%, and 91 . 1% for HR-positive/HER2-low, HR-positive/HER2-zero, HR-negative/HER2-low, and HR-negative/ HER2-zero breast cancers; p \u003C 0 .0001) within strata, with the exception of stage 0.  \nConclusion: In Taiwanese early-stage breast cancer, HER2-low is common and associated with greater HR positivity and modestly inferior OS/RFS relative to HER2-zero after HR and stage stratification. Further studies are warranted to understand the biological and therapeutic relevance of this newly established taxonomy.  \nKeywords: Breast cancer; Cancer registry; HER2-low; HER2-zero; Taiwan  \n354 [www.ejcma.org](www.ejcma.org)  \nOriginal Article. (2026) 89:5 J Chin MedAssoc  \nLay Summary: Human epidermal growth factor receptor II (HER2)-low breast cancer is a newly recognized subgroup within HER2-negative disease and may be relevant for emerging targeted therapies. Using the Taiwan Cancer Registry, we analyzed 38 773 women with early-stage (stages 0-III) HER2-negative breast cancer treated with surgery between 2011 and 2020. HER2-low tumors accounted for 65% of cases and were more likely to be hormone receptor–positive and diagnosed ata slightly younger age than HER2-zero tumors. After stratifying by hormone receptor status and pathological stage, these two factors remained the strongest predictors of survival. Compared with HER2-zero disease, HER2-low breast cancer showed slightly worse overall and relapse-free survival, although differences were small and not evident in stage 0 disease. These findings suggest that HER2-low breast cancer has modest but consistent clinical differences from HER2-zero disease. Identifying HER2-low status in early breast cancer may be important for future treatment planning, particularly if metastatic relapse occurs and HER2-targeted antibody–drug conjugates become applicable.  \n1. INTRODUCTION  \nHuman epidermal growth factor receptor II (HER2)-low breast cancer is","cbCaioq6sdMTHcmh","https://ap.wps.com/l/cbCaioq6sdMTHcmh","pdf",2583679,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What was the main goal of the study on HER2-low versus HER2-zero early breast cancer?\",\"answer\":\"To compare clinicopathological features and outcomes of HER2-low versus HER2-zero early breast cancers and clarify the role of hormone receptor (HR) status in prognosis.\"},{\"question\":\"How were eligible patients selected for analysis?\",\"answer\":\"Eligible cases were stages 0 to III HER2-negative breast cancers treated with upfront surgery, identified from the Taiwan Cancer Registry between 2011 and 2020.\"},{\"question\":\"What were the key survival findings for HER2-low compared with HER2-zero after HR and stage stratification?\",\"answer\":\"Across HR- and stage-defined strata, HER2-low showed modestly higher hazards and small but consistent reductions in overall survival (OS) and relapse-free survival (RFS) versus HER2-zero, except for stage 0 where differences were not evident.\"}]","Clinical presentations and prognostication of HER2-low and HER2-zero early breast cancer in Taiwan | PDF",1790057612,25,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d98dfeb949b34d625659fdea47022446.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/376013c8e8d7fce6da1db7725d5f7056.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f3e2c68c49bde002cb8253cef7cc0a45.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/05982d3366e75fc524086bc4a8371229.webp",980,1306]